Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. METH...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Hochhaus, Andreas, Larson, Richard A., Guilhot, François, Radich, Jerald P., Branford, Susan, Hughes, Timothy P., Baccarani, Michele, Deininger, Michael W., Cervantes, Francisco, Fujihara, Satoko, Ortmann, Christine-Elke, Menssen, Hans D., Kantarjian, Hagop, O’Brien, Stephen G., Druker, Brian J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5901965/
https://ncbi.nlm.nih.gov/pubmed/28273028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1609324
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados